Biogen Idec (NASDAQ:BIIB) is now off its 52-week high of $226.18 (reached earlier today), but up from a 52-week low of $126.39 (as of June 4, 2012). At $218.84 it has risen 73% off the low.
I began following BIIB in the first quarter of 2006, but did not acquire stock until February 2008, when I picked it up at $61.57 per share. In the short run I overpaid, but I picked up more later that year at $46.97. A person with perfect timing could have picked up shares at $40.27 on Nov. 28, 2008. Biogen then rose to $67.05 by the end of 2010, and looks like it invented an anti-gravity machine this January.
Biogen did so well that it became too large a percentage of my portfolio (according to my portfolio rules), so I sold half of my position on May 16, 2012, for $137.19. Now, of course, I wish I had violated my portfolio rules and kept the stock longer. But I had other situations where those same rules kept me out of major trouble -- they were the main reason I sold most of my Dendreon (NASDAQ:DNDN) stake before the price collapsed. Even though my remaining Biogen stake is well within my portfolio rules, I have to ask myself: Is BIIB overpriced? Should I sell it and look for a better value proposition?
There were reasons Biogen was priced where it was in 2008 through 2010, the big one being a disease called PML (progressive multifocal leukoencephalopathy) caused by the JVC virus. Biogen's specialty is multiple sclerosis MS therapies. Its Avonex was the most prescribed MS therapy, but the new wonder drug was supposed to be Tysabri. MS is an autoimmune disease; MS therapies work by selectively suppressing the immune system. Turned out that the JVC virus lurks in the brains of about half of the population, generally doing no harm except when the immune system collapses, when it causes PML and often results in death.
Tysabri use led to some PML cases, and in a few instances to death. Not knowing what the rate was, nor what treatment could be given for PML, the FDA revoked Tysabri's marketing license. The immediate solution turned out to be to monitor for PML and stop giving Tysabri if there were symptoms. The FDA re-approved Tysabri provided a monitoring program was in place. While Tysabri was so effective that sales ramped back up substantially, naturally there was concern by doctors, patients, and investors that we might see more PML deaths and a permanent ban on Tysabri.
Nevertheless, in Q1 2008 Tysabri sales were $115 million, total Biogen revenue was $942 million, and GAAP EPS was $0.54. It being the recession, investors were risk-adverse and it seemed no amount of good news on Tysabri, its revenues, or profits could do much for the stock until late 2010. So much of the run-up in the price was just investors catching up to the new reality: a highly-profitable biotechnology company with a strong pipeline of potential future blockbusters. But in the same way investors lagged reality before 2011, perhaps so many momentum players have jumped on the BIIB bandwagon that the stock has gotten ahead of its fair valuation.
By the beginning of 2013 we had pre-screening for JVC and better treatments for PML, reducing the risk of PML mortality to statistically close to zero. We have substantial Fampyra revenues, though that therapy had also had its issues. Plegridy (peginterferon beta-1a) for relapsing MS pivotal Phase III data has met all primary and secondary endpoints after one-year cutoff of a two-year study. Biogen expects to file with FDA and EMA (Europe) by mid-2013. Daclizumab-HYP Phase III data readout expected in 2014. It is also for relapsing forms of MS. Biogen also filed for approval with FDA for Hemophilia Factor 8 for A and 9 for B, based on significant Phase III trial results. A number of other therapies are in Phase I, II, or III trials. (See the Biogen-Idec product pipeline for more details.)
So, we can figure that the most likely scenario is that Biogen Idec will see substantial revenue and profit growth over the next few years and new therapies come to market. It is unlikely that everything in the pipeline will get good results and FDA approval, but Biogen has a lot of shots on goal.
You can build spreadsheets (and I have, and sell-side analysts certainly do) guessing at revenue and profits from future therapies based on patient populations, competing therapies, and guesses about pricing. But experienced pharmacology and biotechnology investors know that promising therapies often fail, and unexpected side effects can show up even after FDA approval. Picking winners of competitive races is also more guesswork than science. So a good hard look at the latest quarter should keep us anchored in reality, and then some P/E ratio points can be added to reflect optimism about profit growth in the next few years; add as many points as you are comfortable with.
Biogen reported on the first quarter of 2013 last Thursday. Revenue of $1.415 billion was up 9.5% from Q1 2012, which is quite good and means a fair P/E ratio should be above the market average. GAAP EPS was $1.79, up 43% year over year; now that should be worth some a P/E ratio well above market. Ballpark it at 30 to 1. Guidance is for 2013 GAAP EPS of $6.69 to $6.90. Given that non-GAAP guidance is $7.80 to $7.90, let's use $7.00 and multiply by 30. That gives us $210 per share, not much off today's auction price.
So my ballpark estimation is that even at this price BIIB is still a good value. Included in the price are estimated 2013 profits. The pipeline of new drugs revenue and profits won't kick in substantially until 2014. I would expect BIIB to end 2014 in a higher price band, depending on the details of new product ramps.
I am inclined to hold my BIIB, and if I need to sell stock because I spot another opportunity as good as Biogen was in 2008, I could probably find something else to sell. Most likely I will leave BIIB off the leash until it again becomes a risk management problem from being too large a percentage of my portfolio. If I am wrong and it falls in the short run, or becomes a smaller percentage of my portfolio again because something else runs up, I might even buy more. Keep diversified!
Disclaimer: I own shares of BIIB and reserve the right to sell them or buy more at any time, even though I currently have no plans to change my position.